Table 4.
Overlaps among DLBCL classifications and potential therapeutic interventions.
| Cell of origin (46, 47) | DFCI/HMS * (19) | NCI** (20, 21), | HMRN*** (54) | Potential therapeutic interventions^ |
|---|---|---|---|---|
| ABC | C5 | MCD | MYD88 * |
Lenalidomide; BTK inhibition; IRAK4 inhibition; BET inhibition; PI3K/mTOR inhibition; JAK/STAT inhibition; PKCβ inhibition BCL2 and BCL-XL inhibition |
| ABC | * | N1 | * | Immune checkpoints; Notch1 inhibition |
| GCB | C3 | EZB | BCL2 | PI3K/mTOR inhibition; EZH2 inhibition; BCL2 inhibition; MYC inhibition; CREBBP inhibition |
| GCB | C4 | * | SOCS1/SGK1 | JAK/STAT inhibition; BRAF/MEK1 inhibition |
| GCB | * | ST2 | TET2/SGK1 | PI3K inhibition; JAK2 inhibition |
| GCB/ABC | C1 | BN2 | NOTCH2 | BET inhibition; PI3K/mTOR inhibition; Lenalidomide; NF-kB inhibition; PKCβ inhibition; BCL2 inhibition; Notch2 inhibition |
| GCB/ABC | C2 | A53 | NEC | NF-kB inhibition; CDK inhibition |